News Release Details

Pixel by Labcorp® COVID-19 PCR Test Home Collection Kits Now Available Nationwide at Walgreens and Through On-Demand Delivery

Jun 8, 2021 at 4:35 PM EDT

Kit Available Without a Prescription in Stores and Delivered by DoorDash® and Instacart®

BURLINGTON, N.C. & DEERFIELD, Ill.--(BUSINESS WIRE)--Jun. 8, 2021-- Labcorp (NYSE: LH), a leading global life sciences company today announced that Pixel by Labcorp® COVID-19 PCR Test Home Collection Kits are now in 6,000 Walgreens stores nationwide and through Walgreens collaborations with on-demand delivery services DoorDash and Instacart. The newly expanded availability and delivery option advances Walgreens and Labcorp’s efforts to increase COVID-19 testing access in communities across the U.S., especially in underserved areas.

This press release features multimedia. View the full release here:

Photo courtesy of Labcorp

Photo courtesy of Labcorp

“Labcorp’s continued collaboration with Walgreens to make the Pixel by Labcorp COVID-19 PCR Test Home Collection Kit more broadly available helps us support our communities in returning to the activities of our daily lives,” said Brian Caveney, M.D., chief medical officer and president of Labcorp Diagnostics. “The on-demand delivery option is especially useful for individuals who might show symptoms of COVID-19 infection and want to be tested without potentially infecting others. It would also be helpful for people who may not have the flexibility to leave their home but need access to testing.”

Customers will be able to purchase the Pixel by Labcorp COVID-19 PCR Test Home Collection Kit at the pharmacy counter without a prescription, or they can order it for delivery through DoorDash and Instacart. Additionally, the Pixel by Labcorp COVID-19 PCR Test Home Collection Kit is available on Pixel by Labcorp and Walgreens Find Care®, a digital health platform available on the Walgreens app and at The expanded availability of the collection kit will increase customers’ access to testing solutions when and how they need them—at home, in stores, or in-person at one of Walgreens conveniently located testing sites. As recently announced, parents and guardians can request the kits for use with children and adolescents ages 2-17 through the Pixel by Labcorp website.

Customers can self-administer the test collection using a nasal swab and send the sample back to Labcorp via prepaid FedEx Express overnight shipping. Test results will then be available via the Pixel by Labcorp website. If a COVID-19 test is positive, a Labcorp-verified health care staff member will contact the individual to discuss next steps. Pixel by Labcorp has contracted with a physician network to make independent physician services available for consultation.

The Pixel by Labcorp COVID-19 PCR Test Home Collection Kit has not been FDA-cleared or approved, but has been authorized for emergency use by the FDA under an EUA, and has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. Emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. In-store availability is limited and may vary by location.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn more about us at or follow us on LinkedIn and Twitter @Labcorp.

Labcorp Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements with respect to clinical laboratory testing and the potential benefits of a COVID-19 test home collection kit and our responses to and the expected future impacts of the COVID-19 pandemic and the opportunities for future growth.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, whether our response to the COVID-19 pandemic will prove effective, the impact of the COVID-19 pandemic on our business and financial condition, as well as on general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, the Company’s satisfaction of regulatory and other requirements, patient safety issues, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

The Company has no obligation to provide any updates to these forward-looking statements even if our expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.

Labcorp Contacts:
Media: Christopher Allman-Bradshaw – 336-436-8263

Investors: Chas Cook – 336-436-5076

Walgreens Contact:
Emily Mekstan


Source: Labcorp